‘The Psycho-Cultural Dynamics of
Emotion, Power and Politics in
Richard III’
Friday 8th July 2016,
6.30-8pm
Venue:
The Freud Museum, 20 Maresfield Gardens, London NW3 5SX
Tickets:

The Freud Museum in association with Bournemouth University and the Media and Inner World research network present a special panel discussion on the themes of Shakespeare’s Richard III and the motivations of its characters and the play’s relevance for contemporary understandings of emotion and politics. The event includes the performance of some key speeches from the play as performed by actors from the award-winning theatre ensemble, The Faction.
Panel speakers include:
Michael Rustin (University of East London), Margaret Rustin (Tavistock and Portman NHS Trust), Rachel Valentine Smith and Mark Leipacher (The Faction) Chair: Candida Yates (Bournemouth University).
Followed by a drinks reception 8-9pm
& celebration of Candida Yates’ latest book,
The Play of Political Culture, Emotion and Identity, Palgrave Macmillan
Conference: Powerplay: Psychoanalysis and Political Culture; BU at the Freud Museum, 10th December
BU at The Freud Museum: ‘Powerplay: Psychoanalysis and Political Culture’
BU Trauma and Journalism panel at The Freud Museum, Friday, 27 May, 6.30-8pm, Tickets still available!










Official book launch at Bournemouth University
Take a Break: Join the Creative Wellbeing Event
Psychology, Psychiatry and Neuroscience academics – would you like to get more involved in preparing our next REF submission?
Three Minute Thesis (3MT®) 2026: Register to Support our PGRs
Horizon Europe Cluster 3 (Civil Security for Society) 2026 Calls Now Open
MSCA Doctoral Networks 2026 Call Information Webinar
ESRC Festival of Social Science 2026: Application Deadline Extended to Thursday 25 June 2026
Reminder: Register for the ESRC Festival of Social Science 2026 Information Session
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease